CARLSBAD, Calif. & SAN DIEGO--(BUSINESS WIRE)--Invitrogen Corporation (NASDAQ:IVGN), a provider of essential life science technologies for disease research and drug discovery, and Cytori Therapeutics (NASDAQ:CYTX) (Frankfurt:XMPA), entered into a global strategic supply and commercialization agreement to offer adipose-derived stem cell-based research products to life science researchers. Invitrogen will offer Cytori’s stem cell products to broaden the understanding of adult stem cells and to discover and accelerate development of preclinical applications for adipose derived stem cells.
